Plantar, Ramel D.
HRN: 23-91-21 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/10/2024
CEFUROXIME 1.5GM (VIAL)
11/10/2024
11/17/2024
IV
1.5g
Q8
Nasofrontal Mass, For Elective OR
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueProphylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes